Andrew Left takes heat after Valeant report no-show

Citron Research’s Andrew Left is done with troubled pharmaceutical giant Valeant — but not before the short-seller’s𓂃 two sensationalඣ market calls sheared more than $20 billion off the company’s market cap.

On Friday, the well-known short tweeted that he would unveil a blockbuster report o𒅌n Monday that would show how “dirty” Valeant is — and sent the stock down 17 percent.

A week earlier, after a Citron report asked if Valeant is a “pharmaceutical Enron” — that is, booking fake sales — shares of the drugmaker fell 40 percent before�🌄� it recovered half of that.

Left has 🉐backtracked on both of those calls — ✱most recently on Monday.

Actually, Left started to slowly back🥂 awa🔥y from his latest call on Sunday night, he wasn’t going to have a bombshell after all.

When with simply a rehash of widespread criticism♌s of the company, Left called it his “last word” on Valean🧜t.

After perhaps bracing for another attack, investors appeared relieved, sending Valeantﷺ shares up as much as 9 percent o🙈n Monday morning.

Valeant, which has fallen 50 percent since Citron issued its “pharmaceutical Enron” report, closed Monday at $100.55, ꧒up 7.2 percent.

The rise came despite a downgrade by Goldman Sachs and a rebuke by Berkshire Hathaway✨ Vice Chairman Charlie Munger, who said Valeant was “deeply immoral” but not an Enron or a house of cards.

The still-fragile stock jumped a⛎gain after Left grew testy with CNBC reporter Scott Wapner when asked, in an interview, if he was misleading the market with his Friday tweet.

Left accused Wapner of demonizing short-sellers and refused to say if he had a current position in the stock — or whether he♋ had made $150 million on his short, as has been rumored.

“Why don’t you be more transparent? There is so much heat on you. It’s going to come out anyway,” Wapner said, in an apparent reference to Valeant’s request toꦕ the Securities and Exchange Commission that it 🀅investigate Left.

Valeant had claimed Left sho♏uted “fire in a crowded theater” to push the stock down so he could profit off his short po𝓰sition.

Last week, Left told The Post he decided not to sue Valeant after conferring with his l♏awyer. On Monday, he said he was going to give all his research to mainstream media because they have “deeper legal teams.”

The media outlets seem to be doing OK on their own, as several journalists have exposed Valeant’s relationship with specialty pharma Philidor and detailed allไegations of improprieties related to it.

Valeant cut its ties with Philidor on Friday after three pharmacy benefit managers kicked Philidor out of their net�🅰�works.